Sun Pharma Advanced Research Company Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/tddc3a8luyc7p79fu64tulsx.pdf

Key Takeaways


The PROSEEK Failure: What Happened and What It Means

Raghavan: "That was indeed a disappointing outcome, and certainly not what we hoped for our patients, especially after having generated significant body of evidence in preclinical model systems... demonstrating the neuroprotective role of Vodobatinib in multiple pre-clinical studies."

Financial Position and Runway

Raghavan: "Obviously these results represent a setback for SPARC which will pose questions on certain parts of our portfolio and challenge our ability to pursue an aggressive R&D agenda."

Leukemia Franchise: The Licensing Pivot


Early-Stage Pipeline: The New Value Drivers


Commercial Products: Incremental, Not Transformational


Guidance & Commitments

CommitmentSpecificsTimeline
PROSEEK full data analysisComplete analysis of all data including PKQ2 FY25
Vodobatinib CML out-licensingFinalize licensing partner for all leukemia settingsThis financial year
SCO-088 licensing dealPartner asset to raise non-dilutive capitalThis financial year
SCD-153 Phase I completionComplete single ascending dose and patient studyBy FY25
SCD-153 early patient studyStudy in alopecia areata patients in IndiaBy FY26
SBO-154 IND filingFile IND for ADC programBefore end of current financial year (by Mar 2025)
Vibozilimod SOLARES top-line resultsAtopic dermatitis Phase II data readoutQ4 2024
PDP-716 refilingRefiling with regulatorSeptember 2024 timeline
Cash runwayCurrent cash plus credit funds operations12–15 months

Key Metrics

MetricQ4 FY24
PROSEEK primary endpointNot met (change in MDS-UPDRS Part III at week 40 vs placebo)
PROSEEK patients reviewed in interim analysis442 of 513 randomized patients completed Part I by March 2024
PROSEEK trial statusClosed based on statistical projections of unlikely benefit in overall population
PROSEEK full analysis expectedQ2 FY25
PROSEEK total budget$45 million range, with savings expected from early termination
PROSEEK spend to dateIn excess of $35 million, between $35 million and $40 million, closer to $35 million
Current cash balanceAround $20 million
Cash runway12–15 months from current cash and approved credit, factoring in cost savings from reprioritization
SCO-088 (Vodobatinib CML) statusPhase 2 completed, registration study design discussions with USFDA underway
SCO-088 licensing objectiveTargeting this financial year
CML opportunity sizeSeveral hundred million dollars (vs several billion for Parkinson's)
Vibozilimod SOLARES AD top-line resultsQ4 2024
SCD-153 Phase 1 completionBy FY25, early patients' study in Alopecia Areata in India by FY26
SBO-154 IND filingBy end of current financial year
Phenobarbital exclusivity expectedEnd of second year or beginning of third year of launch